



RNS REACH: RELEASE

4 June 2026

ImmuPharma PLC
("ImmuPharma" or the "Company")

Incanthera plc – Corporate Update & Board Changes

ImmuPharma plc (LSE AIM: IMM), the specialist drug discovery and development company, notes today's announcement by Incanthera plc, "Incanthera", regarding a corporate update and subsequent Board changes. As part of the Board changes, Tim McCarthy has stepped down as Executive Chairman of Incanthera: Link: <https://incanthera.com/news-media/>.

Ends

ImmuPharma PLC (www.immupharma.co.uk)

Tim McCarthy, Chief Executive Officer and Chairman
Lisa Baderoon, Head of Investor Relations

+ 44 (0) 7721 413496

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

+44 (0) 203 368 8974

Stanford Capital Partners (Joint Broker)

Patrick Claridge, Bob Pountney

+44 (0) 203 650 3650

SI Capital (Joint Broker)

Nick Emerson

+44 (0) 1483 413500

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives.

For additional information about ImmuPharma please visit www.immupharma.co.uk.

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

About Reach announcements

Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.